Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.

Mark D. Linch, MD, Matthew W. Jenner, MD, Sharon Dines, Faith E. Davies, MD, Gareth J. Morgan, PhD

Blood (2007) 110 (11): 4841.

https://doi.org/10.1182/blood.V110.11.4841.4841

Published: 2007

Journal Articles

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

Gareth J. Morgan, PhD, Stephen Schey, MD, Ping Wu, M. Srikanth, MD, Karen J. Phekoo, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Faith E. Davies, MD

Blood (2006) 108 (11): 3555.

https://doi.org/10.1182/blood.V108.11.3555.3555

Published: 2006

Journal Articles

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Faith E. Davies, MD, Ping Wu, M. Srikanth, MD, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Gareth J. Morgan, PhD

Blood (2006) 108 (11): 3537.

https://doi.org/10.1182/blood.V108.11.3537.3537

Published: 2006

Journal Articles

Identification of Collaborating Oncogeneic Events Leading to Disease Progression in Myeloma Cases with a t(4;14) and t(11;14) Using SNP and Gene Expression Arrays.

Matthew W. Jenner, MD, Brian A. Walker, PhD, Paola E. Leone, PhD, David Gonzalez, PhD, Fiona M. Ross, PhD, Cheng Li, PhD, Faith E. Davies, MD, Gareth J. Morgan, PhD

Blood (2005) 106 (11): 1542.

https://doi.org/10.1182/blood.V106.11.1542.1542

Published: 2005

Journal Articles

Newly Diagnosed Myeloma Pateints Are at Risk of Venous Thrombotic Events - High Risk Patients Need To Be Identified and Recieve Thromboprophylaxis: The MRC Experience.

Faith E. Davies, MD, J. Anthony Child, MD, Kim Hawkins, MSc, Susan Bell, DPhil, Julia Brown, MSc, Mark T. Drayson, PhD, Graham H. Jackson, PhD, Gareth J. Morgan, PhD

Blood (2004) 104 (11): 2395.

https://doi.org/10.1182/blood.V104.11.2395.2395

Published: 2004

Journal Articles

The Bone Marrow Microenvironment Influences the Differential Chemokine Receptor Expression of Normal and Neoplastic Plasma Cells.

Faith E. Davies, MD, Mona H. Al Rayes, J. Anthony Child, MD, Gareth J. Morgan, PhD, Andrew C. Rawstron, PhD

Blood (2004) 104 (11): 2353.

https://doi.org/10.1182/blood.V104.11.2353.2353

Published: 2004

Journal Articles

Follow up Analysis for MRC Myeloma VII Trial.

Gareth J. Morgan, PhD, Faith E. Davies, MD, Kim Hawkins, MSc, Susan E. Bell, DPhil, Julia M. Brown, MSc, Roger G. Owen, MD, Mark T. Drayson, PhD, Peter J. Selby, MD, Anthony J. Child, MD, for the Medical Research Council Adult Leukaemia Working Party

Blood (2004) 104 (11): 927.

https://doi.org/10.1182/blood.V104.11.927.927

Published: 2004

NARROW

Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Identification of Collaborating Oncogeneic Events Leading to Disease Progression in Myeloma Cases with a t(4;14) and t(11;14) Using SNP and Gene Expression Arrays.

Newly Diagnosed Myeloma Pateints Are at Risk of Venous Thrombotic Events - High Risk Patients Need To Be Identified and Recieve Thromboprophylaxis: The MRC Experience.

The Bone Marrow Microenvironment Influences the Differential Chemokine Receptor Expression of Normal and Neoplastic Plasma Cells.

Follow up Analysis for MRC Myeloma VII Trial.

Email alerts

ASH Publications

American Society of Hematology

Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Identification of Collaborating Oncogeneic Events Leading to Disease Progression in Myeloma Cases with a t(4;14) and t(11;14) Using SNP and Gene Expression Arrays.

Newly Diagnosed Myeloma Pateints Are at Risk of Venous Thrombotic Events - High Risk Patients Need To Be Identified and Recieve Thromboprophylaxis: The MRC Experience.

The Bone Marrow Microenvironment Influences the Differential Chemokine Receptor Expression of Normal and Neoplastic Plasma Cells.

Follow up Analysis for MRC Myeloma VII Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only